Posts by Shauneen Beukes

Aspen opens anaesthetic building as part of €100 million investment at its French-based site

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has expanded its specialist sterile production site at Notre Dame de Bondeville in France to augment the Group’s global manufacturing facilities. Stephen Saad, Aspen Group Chief Executive said, “The new state-of-the-art facility for anaesthetics, together with the new high-speed…

Read More

Department of Health and PHEF celebrate investment in human resources

The South African National Department of Health (NDoH) and the Public Health Enhancement Fund (PHEF) celebrated their investment in human resources for health in honour of the late Prof Bongani Mayosi on 30 April 2019. The public and private healthcare sector leaders and professionals converged in honour of post-graduate and medical doctors from various healthcare…

Read More

Aspen approved for secondary listing on A2X

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has been approved for a secondary listing on A2X Markets with effect from 1 April 2019. Stephen Saad, Aspen Group Chief Executive said, “We continually strive to identify ways to increase value for our shareholders and the complementary A2X…

Read More

Aspen’s encouraging Emerging Market growth

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced interim financial results for the six months ended 31 December 2018 in line with management’s expectations. Stephen Saad, Aspen Group Chief Executive said, “Revenue increases from Anaesthetics in China and Latin America of 6% and 22% respectively…

Read More

Aspen launches novel ARV Combination: Set to further improve treatment options

Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option. EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will…

Read More

Aspen’s participation in the 2018 Investment Conference

Sandton – Aspen welcomes President Ramaphosa’s inaugural Investment Conference, aimed at positioning South Africa as a preferred investment destination and at establishing a more predictable and stable investment environment in our country. Amongst other initiatives, this includes facilitating the ease of doing business and reducing unnecessary regulatory burden in the South African pharmaceutical sector. These…

Read More

Aspen supports the World Thrombosis Day campaign

Aspen remains committed to the World Thrombosis Day campaign to raise awareness of thrombosis as an urgent and growing public health problem. PARIS, FRANCE – Aspen has reinforced its commitment to fight thrombosis worldwide through its long-standing partnership with the International Society on Thrombosis and Haemostasis (ISTH) World Thrombosis Day (WTD) campaign. This initiative aims to…

Read More